Revolutionizing Chronic Hepatitis B Treatment: AusperBio's AUSHINE Study
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., together known as AusperBio, are leading the way in innovative treatments for chronic hepatitis B (CHB). Recently, they announced the significant achievement of completing patient enrollment in their pivotal Phase III AUSHINE clinical trial, which focuses on the efficacy and safety of AHB-137, an injection aimed at patients with HBeAg-negative CHB.
The AUSHINE study is a critical, randomized, double-blind trial that marks a key advancement in the field of hepatitis B therapy. There is a pressing need for effective treatments as CHB remains a significant global health challenge, affecting millions of individuals worldwide. The World Health Organization estimates that roughly 254 million people live with chronic hepatitis B virus (HBV) infection, with around 1.2 million new cases reported annually. Notably, a staggering 75 million individuals in specific regions are chronically infected.
Professor Jian Sun, who serves as the principal investigator and President of Nanfang Hospital at Southern Medical University, emphasized the urgency of finding a curative treatment for the majority of HBeAg-negative CHB patients who are currently reliant on long-term nucleos(t)ide analogue therapy. He shared, "For these patients, the current treatment options are primarily suppressive, and achieving a functional cure remains a critical goal. Completing patient enrollment for this Phase III study is a pivotal step in bridging this substantial treatment gap, and we hope AHB-137 can offer a breakthrough for these individuals."
Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, also highlighted the importance of this milestone. The company successfully enrolled over 570 patients in just five months after receiving approval from regulatory bodies, showcasing the commitment and collaboration of clinical teams, investigators, and patients alike. Dr. Cheng stated, "This achievement underscores our dedication to finding a functional cure for chronic hepatitis B, and we are thankful for the partnerships that have made this possible. With a strong scientific foundation, we remain focused on guiding AHB-137 through a comprehensive registrational pathway to deliver transformative treatments."
As part of this innovative therapeutic approach, Dr. Chris Yang, Co-founder and CSO of AusperBio, discussed the study’s rapid progress, stating, "The completion of the Phase III AUSHINE study enrollment ahead of our timeline positions us well for an expedited pathway to primary endpoint results. The exceptional pace of enrollment demonstrates urgent clinical needs for novel HBV treatments and highlights the promising safety and efficacy profile observed for AHB-137. Our early results, which show a potential functional cure rate of about 30%, reinforce our optimism in the capabilities of this cutting-edge therapy."
Understanding AHB-137: Mechanism and Promise
AHB-137 represents a groundbreaking approach through its design as an unconjugated antisense oligonucleotide (ASO). Developed utilizing AusperBio’s proprietary Med-Oligo™ ASO technology platform, this therapy targets chronic hepatitis B towards achieving a functional cure. AHB-137 operates through three complementary mechanisms: it suppresses HBsAg transcription, inhibits viral DNA replication, and reactivates the immune system.
Clinical outcomes have been promising, with multiple key findings showcased at international hepatology conferences, contributing to the evolving understanding of effective HBV treatments. Currently, AHB-137 has successfully concluded its Phase I study and is undergoing multiple Phase II studies and its Phase III trial in China, reinforcing the global strategy to deliver a transformative solution for hepatitis B infection.
AusperBio: Committed to Transforming Hepatitis B Treatment
As a clinical-stage biopharmaceutical firm with operations spanning the USA and China, AusperBio is focused on harnessing advanced oligonucleotide therapies and targeted delivery systems aimed at revolutionizing treatment modalities. Their proprietary Med-Oligo™ ASO platform enhances existing oligonucleotide therapeutics, which is supported by a strategy to address various diseases, including viral infections, immune diseases, and muscle disorders.
AusperBio is dedicated to providing innovative therapies, especially in the realm of chronic hepatitis B, with the goal of helping patients achieve effective outcomes and a better quality of life. As they continue to advance AHB-137 through clinical trials, their commitment to transformative healthcare solutions remains strong.
Frequently Asked Questions
What is the AUSHINE study?
The AUSHINE study is a Phase III clinical trial evaluating the safety and efficacy of AHB-137 in patients with chronic hepatitis B.
What is AHB-137?
AHB-137 is an antisense oligonucleotide therapy designed to target chronic hepatitis B and aims to achieve a functional cure.
Why is this study significant?
This study addresses a major unmet need for effective treatments in a large population of patients suffering from chronic hepatitis B.
Who is involved in the study?
The study includes collaborations between AusperBio, clinical investigators, and participating patients across various locations.
What are the potential outcomes of the AUSHINE study?
The study aims to evaluate AHB-137's ability to deliver a functional cure and can reshape current treatment practices for chronic hepatitis B.
